12556688

Source:http://linkedlifedata.com/resource/pubmed/id/12556688

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0019704, umls-concept:C0021311, umls-concept:C0021756, umls-concept:C0087111, umls-concept:C0205195, umls-concept:C0282440, umls-concept:C0439662, umls-concept:C0887947, umls-concept:C1096777, umls-concept:C1280500
pubmed:issue	3
pubmed:dateCreated	2003-1-30
pubmed:abstractText	Intermittent interleukin-2 (IL-2) therapy leads to a sustained increase of CD4 T cells in HIV-1-infected patients.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8710219
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic, http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0269-9370
pubmed:author	pubmed-author:ANRS 079 Study Group, pubmed-author:AboulkerJean-PierreJP, pubmed-author:CapitantCatherineC, pubmed-author:DelfraissyJean-FrançoisJF, pubmed-author:DurierChristineC, pubmed-author:EmilieDominiqueD, pubmed-author:GastautJean-AlbertJA, pubmed-author:GoujardCécileC, pubmed-author:KrzysiekRomanR, pubmed-author:LascauxAnne-SophieAS, pubmed-author:LevyYvesY, pubmed-author:MaralJeanJ, pubmed-author:MichonChristopheC, pubmed-author:OksenhendlerEricE, pubmed-author:RabianClaireC, pubmed-author:RouziouxChristineC, pubmed-author:WeissLaurenceL
pubmed:issnType	Print
pubmed:day	14
pubmed:volume	17
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	343-51
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:12556688-Adjuvants, Immunologic, pubmed-meshheading:12556688-Administration, Cutaneous, pubmed-meshheading:12556688-Adult, pubmed-meshheading:12556688-Aged, pubmed-meshheading:12556688-Antibody Formation, pubmed-meshheading:12556688-Antiretroviral Therapy, Highly Active, pubmed-meshheading:12556688-CD4 Lymphocyte Count, pubmed-meshheading:12556688-CD4-Positive T-Lymphocytes, pubmed-meshheading:12556688-DNA, Viral, pubmed-meshheading:12556688-Drug Therapy, Combination, pubmed-meshheading:12556688-Female, pubmed-meshheading:12556688-HIV Infections, pubmed-meshheading:12556688-Humans, pubmed-meshheading:12556688-Interleukin-2, pubmed-meshheading:12556688-Male, pubmed-meshheading:12556688-Middle Aged, pubmed-meshheading:12556688-Phenotype, pubmed-meshheading:12556688-RNA, Viral, pubmed-meshheading:12556688-Treatment Outcome, pubmed-meshheading:12556688-Viral Load
pubmed:year	2003
pubmed:articleTitle	Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial.
pubmed:affiliation	Unit of Clinical Immunology, Hospital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil Cedex, France.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study